Can you stack Mazdutide with Survodutide?

Some users run them together. Whether the combination makes sense depends on mechanism overlap, side-effect stacking, and goal. See the protocols on the Mazdutide entry (https://pepdex.co/peptides/mazdutide) and the Survodutide entry (https://pepdex.co/peptides/survodutide) for full stacking notes.

What's the dose difference between Mazdutide and Survodutide?

Mazdutide: Start 3 mg weekly. Titrate to 6-9 mg over 4-week steps based on tolerance. Survodutide: Start 0.3 mg sub-q weekly. Titrate over 4-week steps up to 6.0 mg in trials.

Side effects of Mazdutide vs Survodutide?

Mazdutide most common: Nausea; Constipation or diarrhea; Mild fatigue. Survodutide most common: Nausea (especially titration steps); Diarrhea or constipation; Mild fatigue. Full safety detail on each entry page.

← Back to peptides

Comparison

Mazdutide vs Survodutide

Q: Is Mazdutide or Survodutide FDA approved?

Mazdutide: Not FDA approved. Approved in China (2025, Innovent, brand Xinermei) for obesity and type 2 diabetes. Eli Lilly holds ex-China rights (LY-3305677) and runs US development (Phase 2). Survodutide: Investigational. Phase 3 trials by Boehringer Ingelheim and Zealand Pharma (co-developers).

Mazdutide vs Survodutide: two late-stage GLP-1 + glucagon dual agonists. Innovent vs Boehringer Ingelheim development paths.

The verdict

Same drug class, different developers and timelines. Both are GLP-1 + glucagon dual agonists, where the glucagon arm adds a metabolic-rate boost on top of GLP-1 appetite control. Mazdutide (Innovent) is further along and already approved in China for obesity. Survodutide (Boehringer Ingelheim) is still working through global trials and draws extra interest for its liver-disease data. If availability is the deciding factor, Mazdutide is the one that's actually approved somewhere. Survodutide is the one to watch on the global and metabolic-liver front.

№ 034

Mazdutide

Fat LossEvidence: Moderate

Mazdutide is a Chinese-developed GLP-1 + glucagon dual agonist, same class as Survodutide and Retatrutide. Approved in China in 2025 for obesity. The glucagon part adds a metabolic-rate bump on top of GLP-1's appetite suppression.

Onset

Documentation

Side intensity

Popularity

№ 023

Survodutide

Fat LossEvidence: Moderate

Survodutide is Boehringer Ingelheim's dual agonist (GLP-1 + glucagon), a competitor to Retatrutide. Stronger fat-burn signal than the GLP-1-only drugs because it activates glucagon, which boosts metabolic rate. Phase 2 data is promising. Once-weekly.

Onset

Documentation

Side intensity

Popularity

Side-by-side

Field

Left

Right

Which one should you pick?

Pick Mazdutide if users wanting a glp/glucagon agonist with cleaner side effect profile than survodutide reports or followers of chinese metabolic-drug development.

Pick Survodutide if users plateaued on glp-1-only drugs or people targeting >15% body weight loss.

AI Coach · free

Still torn between Mazdutide and Survodutide?

The AI Coach reads both, asks about your goal and experience, and tells you which one actually fits — plus how to dose and stack it. Free.

Ask the Coach: Mazdutide vs Survodutide →